Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2025-08-18 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
关于召开2025年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 half-year performance explanation meeting (业绩说明会) for investors. It references the company's 2025 half-year report already disclosed on August 19, 2025, and invites investors to participate in an interactive online session to discuss the half-year results. The document does not contain actual financial statements or detailed financial analysis but serves as a notice for the upcoming investor presentation event. The document length is short (1540 characters), and it primarily announces the meeting rather than providing the report itself. Therefore, it fits the category of Investor Presentation (IP).
2025-08-18 Chinese
关于2025年半年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage, management, and actual use of funds raised by the company during the 2025 half-year period. It references regulatory rules from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes specific financial figures related to fundraising, usage, and balances. The document is titled as a "special report" on fundraising usage for the half-year period ending June 30, 2025. It contains substantive financial data and analysis about the fundraising activities and their deployment, not just an announcement or certification. This matches the characteristics of a specialized financial report on capital raising and usage, which aligns best with the category "Capital/Financing Update (CAP)". It is not an annual or interim report, nor an earnings release or audit report. It is not a simple announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2025-08-18 Chinese
独立董事专门会议第一次会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors' special meeting of the board of directors of a company. It discusses the review and approval of a special report on the storage, management, and actual use of raised funds for the half-year period of 2025. The content focuses on board-level approval and compliance with regulatory rules regarding fundraising. This is a board/management information document related to internal governance and oversight rather than a full financial report or announcement of voting results. The document length is short and it is not a report publication announcement. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-08-18 Chinese
和元生物技术（上海）股份有限公司2025年限制性股票激励计划首次授予事项之法律意见书
Regulatory Filings
2025-07-23 Chinese
董事会薪酬与考核委员会关于公司2025年限制性股票激励计划首次授予激励对象名单的审核意见(截止授予日)
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the initial grant list of a 2025 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and approval of the grant details. This content pertains to executive compensation and stock incentive plans, which falls under Remuneration Information filings. The document is not an announcement of a report, nor a full financial report, but a detailed remuneration-related committee opinion.
2025-07-23 Chinese
关于向2025年限制性股票激励计划激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial grant of restricted stock under a 2025 restricted stock incentive plan by the company 和元生物技术（上海）股份有限公司. It details the number of shares granted, the grant date, the recipients, the grant price, the legal and procedural compliance, and the accounting treatment of the stock-based compensation. The document is a formal disclosure of a share-based incentive plan grant to employees and management, including board approval and legal opinions. This type of document is a capital/financing update related to equity incentives and share grants, not a full financial report or audit report. It does not contain financial statements or earnings data but focuses on share-based compensation and equity incentive plan implementation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback.
2025-07-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.